Data show that 65 percent of participants demonstrated the maximal improvement in the clinical trial’s primary endpoint, bilateral multi-luminance mobility testing (MLMT), at year one
Bpifrance and Foundation Fighting Blindness have launched SparingVision to develop vision-saving treatment for Inherited Retinal Diseases. The newly established French company, SparingVision has won the 2017 i-Lab Grand Prize recognizing new and innovative companies. The i-Lab competition is organized by the French Ministry of Higher Education, Research and Innovation and Bpifrance (BPI).
ProQR Therapeutics N.V. has announced that the company’s investigational drug QRX-411 has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is the leading cause of combined deafness and blindness due to genetic defects in the Usher gene.
The 18th International Symposium on Retinal Degeneration will be held in Killarney, Co Kerry, Ireland on September 3-8, 2018. The venue is the Victorian Hotel ‘The Malton’ in Killarney town.
The Foundation Fighting Blindness (FFB) today announced $6 million in new research funding across a spectrum of potential preventions, treatments and cures for inherited retinal diseases including retinitis pigmentosa and macular degeneration. With this new funding, FFB now supports 101 research projects conducted by over 150 investigators at 61 institutions worldwide.
Information from, THe Department of Transplantation Immunology, Institute of Experimental Medicine of the, Czech Academy of Sciences, Prague, Czech Republic.